Multiple Myeloma

Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated  in patients with heavily pretreated relapsed or refractory multiple myeloma.

The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials.

The hematologist and medical oncologist discussed the approval of daratumumab and hyaluronidase-fihj for use in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.

The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.

Karyopharm Therapeutics announced plans to commence a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19.

A case study of a patient in Wuhan, China demonstrated that tocilizumab may be an effective treatment for very ill patients with COVID-19 who also have multiple myeloma and other blood cancers.

Researchers indicated that these results show the feasibility of this regimen and support the development of additional studies of melflufen in multiple myeloma, both in combination with dexamethasone as well as in triplet regimens.

ONCOLOGY recently sat down with Kenneth C. Anderson, MD, to discuss the current trends in multiple myeloma treatment, and the explosion of novel therapies that are paving the way to better and more durable outcomes and allowing patients to live longer and more meaningful lives.

The FDA approved isatuximab-irfc, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor.

The Mayo Clinic expert spoke about stem cell transplantation for patients with myeloma and the factors that affect the ability to collect stem cells.

The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma.

The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.

The associate professor of clinical medicine discussed the main side effects of CAR T-cell therapies when treating multiple myeloma, and how to combat them.

In a workshop conducted by the FDA and AACR, researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications.

Janssen Pharmaceutical Companies submitted a supplemental biologics license application for daratumumab in combination with carfilzomib and dexamethasone to treat patients with relapsed/refractory multiple myeloma.

The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.

Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.

The study evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease did not produce statistically significant results.

In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to treating patients with relapsed/refractory multiple myeloma

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

Sham Mailankody, MBBS, discussed the challenge of determining an optimal sequence of treatments in patients with relapsed/refractory multiple myeloma, and how head-to-head studies can help.

Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.

In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to implement shared decision-making when discussing treatment options with your patients.